Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>Longeveron is focusing on using its primary treatment, laromestrocel, to fight a rare pediatric heart birth defect that devastates families and continues to receive good FDA news regarding its treatment for Alzheimer's Disease, while also expanding its pipeline.</li><li> The company announced its 3Q 2025 earnings results that showed good cost discipline, while giving a timeline for the path to commercialization.</li><li>The company is at an inflection point, and we are optimistic about the direction the company will take.</li></ul>

Longeveron is focusing on using its primary treatment, laromestrocel, to fight a rare pediatric heart birth defect that devastates families and continues to receive good FDA news regarding its treatment for Alzheimer's Disease, while also expanding its pipeline. The company announced its 3Q 2025 earnings results that showed good cost discipline, while giving a timeline for the path to commercialization.The company is at an inflection point, and we are optimistic about the direction the company will take.

LGVN: Approaching an Exciting Inflection Point